Updated:
Nu-Med Plus
Nu-Med Plus: Jeffrey Robins leads this Salt Lake City medical device firm developing nitric oxide delivery systems for critical-care settings since 2012.
Nu-Med Plus
Nu-Med Plus, Inc. was incorporated in Utah in 2012 by President and CEO Jeffrey L. Robins. The company operates as a medical device research and development firm focused on creating novel nitric oxide delivery and monitoring technologies. It is a public company, trading on the OTC Markets, and maintains its headquarters in Salt Lake City, Utah. The company's primary technical focus is on improving the precision and safety of therapeutic nitric oxide (NO) administration. Nitric oxide is a critical vasodilator used in neonatal and adult intensive care for conditions such as persistent pulmonary hypertension. Nu-Med Plus's R&D pipeline includes advancements in NO delivery systems that incorporate real-time monitoring and enhanced metering to reduce the risk of methemoglobinemia. The firm has explored applications for both hospital-based devices and portable, lightweight systems for extended-use care settings. As a micro-cap R&D entity, Nu-Med Plus operates principally as a clinical-stage developer. The company has historically funded operations through private placements and equity issuances. In May 2024, the company's management has maintained a lean operating structure, emphasizing patent protection for its delivery apparatus intellectual property rather than direct manufacturing scale-up. Nu-Med Plus's structural differentiator lies in its singular focus on the delivery mechanism within a mature pharmaceutical gas market. While established players dominate the bulk production and sales of nitric oxide gas, Nu-Med Plus has carved a niche around the patented hardware and algorithms used to titrate, meter, and monitor the dosage, positioning itself as a potential acquisition target or licensing partner for larger medical device conglomerates.
General information
Firm type
other
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Salt Lake City
Corporate office
Salt Lake City, UT, United States
Principals
Jeffrey L. Robins
Chief Executive Officer, President, and Director
Thomas E. Tait
Chief Financial Officer, Principal Accounting Officer, Secretary, and Treasurer
Sector focus
Frequently asked questions
What is Nu-Med Plus's primary area of research?
Nu-Med Plus focuses on developing advanced nitric oxide (NO) delivery and monitoring systems. Its work centers on creating devices that can administer precise doses of NO, a pulmonary vasodilator, while continuously monitoring key parameters to prevent toxicity. The target users are hospitals treating conditions like hypoxic respiratory failure in newborns.
How is Nu-Med Plus different from the major industrial gas companies that also sell nitric oxide?
Nu-Med Plus does not manufacture or sell nitric oxide gas itself. Instead, it develops and patents the delivery hardware, sensor integrations, and metering software. This positions the company as a pure-play medical device developer whose intellectual property could complement the bulk gas distribution networks of larger industrial players.
Is Nu-Med Plus a pre-revenue, research-stage company?
Based on its public filings, Nu-Med Plus is largely a pre-revenue research and development enterprise. Its financial activity has been directed toward obtaining patents, conducting R&D, and meeting the regulatory requirements to move its delivery systems toward eventual commercial clearance.
Who are the key executives at Nu-Med Plus?
The senior leadership includes Jeffrey L. Robins, who serves as President, Chief Executive Officer, and a Director, driving the company's technical and strategic vision. Thomas E. Tait acts as the Chief Financial Officer and Principal Accounting Officer, managing the firm's financial reporting and administrative functions.
On what public market does Nu-Med Plus trade, and what is its status?
Nu-Med Plus is a publicly traded company on the OTC Markets under the ticker symbol NUMD. Its public status provides a mechanism for capital raising but operates with the liquidity and reporting standards typical of a micro-cap firm in the developmental stage.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: